Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02501811
Recruitment Status : Active, not recruiting
First Posted : July 17, 2015
Last Update Posted : January 29, 2020
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Barry R Davis, The University of Texas Health Science Center, Houston

Brief Summary:
This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.

Condition or disease Intervention/treatment Phase
Ischemic Cardiomyopathy Biological: Mesenchymal Stem Cells (MSC) Biological: c-kit+ cells Biological: Placebo (Plasmalyte A) Phase 2

Detailed Description:
This is a randomized, placebo-controlled clinical trial designed to evaluate the feasibility, safety, and effect of Combo, MSCs alone, and c-kit+ cells alone compared with placebo as well as each other in subjects with heart failure of ischemic etiology. Following a successful lead-in phase, a total of one hundred forty-four (144) subjects will be randomized (1:1:1:1) to receive Combo, MSCs, c-kit+ cells, or placebo. After randomization, baseline imaging, relevant harvest procedures, and study product injection, subjects will be followed up at 1 day, 1 week, 1 month, 3 months, 6 months and 12 months post study product injection. All subjects will receive study product injection (cells or placebo) using the NOGA® XP Mapping and Navigation System. Subjects will have delayed-enhanced magnetic resonance imaging (DEMRI) scans to assess scar size and LV function and structure at baseline and at 6 and 12 months post study product administration. All endpoints will be assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days respectively from the day of study product injection (Day 0). For the purpose of the endpoint analysis and safety evaluations, the Investigators will utilize an "intention-to-treat" study population, however an as treated analysis will also be conducted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic Heart Failure
Study Start Date : October 2015
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mesenchymal Stem Cells (MSC)
Target dose of 150 million MSCs
Biological: Mesenchymal Stem Cells (MSC)
15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Experimental: c-kit+ cells
Target dose of 5 million c-kit+ cells
Biological: c-kit+ cells
15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Experimental: Combination Cells (MSC and c-kit+ cells)
Target dose of 150 million MSCs and 5 million c-kit+ cells
Biological: Mesenchymal Stem Cells (MSC)
15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Biological: c-kit+ cells
15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Placebo Comparator: Placebo (Plasmalyte A)
Plasmalyte A
Biological: Placebo (Plasmalyte A)
15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Other Name: Plasmalyte A




Primary Outcome Measures :
  1. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in left ventricular ejection fraction as assessed via cardiac MRI

  2. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Baseline to 6 months ]
    Change in left ventricular ejection fraction as assessed via cardiac MRI

  3. Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Baseline to 12 months ]
    Change in left ventricular ejection fraction as assessed via cardiac MRI

  4. Global Strain (HARP MRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in global circumferential strain as assessed via cardiac MRI

  5. Global Strain (HARP MRI) [ Time Frame: Baseline to 6 months ]
    Change in global circumferential strain as assessed via cardiac MRI

  6. Global Strain (HARP MRI) [ Time Frame: Baseline to 12 months ]
    Change in global circumferential strain as assessed via cardiac MRI

  7. Regional Strain (HARP MRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in regional longitudinal strain as assessed via cardiac MRI

  8. Regional Strain (HARP MRI) [ Time Frame: Baseline to 6 months ]
    Change in regional longitudinal strain as assessed via cardiac MRI

  9. Regional Strain (HARP MRI) [ Time Frame: Baseline to 12 months ]
    Change in regional longitudinal strain as assessed via cardiac MRI

  10. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI

  11. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Baseline to 6 months ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI

  12. Left Ventricular End Diastolic Volume Index (LVEDVI) [ Time Frame: Baseline to 12 months ]
    Change in left ventricular end diastolic volume index as measured via cardiac MRI

  13. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, 12 months) ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI

  14. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Baseline to 6 months ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI

  15. Left Ventricular End Systolic Volume Index (LVESVI) [ Time Frame: Baseline to 12 months ]
    Change in left ventricular end systolic volume index as assessed via cardiac MRI

  16. Left Ventricular Sphericity Index [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in left ventricular sphericity as assessed via cardiac MRI

  17. Left Ventricular Sphericity Index [ Time Frame: Baseline to 6 months ]
    Change in left ventricular sphericity as assessed via cardiac MRI

  18. Left Ventricular Sphericity Index [ Time Frame: Baseline to 12 months ]
    Change in left ventricular sphericity as assessed via cardiac MRI

  19. Infarct/scar Volume (DEMRI) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in infarct/scar volume as assessed via cardiac MRI

  20. Infarct/scar Volume (DEMRI) [ Time Frame: Baseline to 6 months ]
    Change in infarct/scar volume as assessed via cardiac MRI

  21. Infarct/scar Volume (DEMRI) [ Time Frame: Baseline to 12 months ]
    Change in infarct/scar volume as assessed via cardiac MRI

  22. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill

  23. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Baseline to 6 months ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill

  24. Maximal Oxygen Consumption (VO2 max) [ Time Frame: Baseline to 12 months ]
    Change in maximal oxygen consumption (V02 max) as assessed via treadmill

  25. Exercise Tolerance [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in exercise tolerance as assessed via the 6 minute walk test

  26. Exercise Tolerance [ Time Frame: Baseline to 6 months ]
    Change in exercise tolerance as assessed via the 6 minute walk test

  27. Exercise Tolerance [ Time Frame: Baseline to 12 months ]
    Change in exercise tolerance as assessed via the 6 minute walk test

  28. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score

  29. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Baseline to 6 months ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score

  30. Minnesota Living with Heart Failure Questionnaire (MHLFQ) Score [ Time Frame: Baseline to 12 months ]
    Change in Minnesota Living with Heart Failure Questionnaire (MHLFQ) score

  31. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Assessed as a trajectory (baseline, 6 months, and 12 months) ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw

  32. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Baseline to 6 months ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw

  33. N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) [ Time Frame: Baseline to 12 months ]
    Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via blood draw

  34. Incidence of major adverse cardiac events (MACE) [ Time Frame: Baseline to 6 months ]
    Incidence of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization)

  35. Incidence of major adverse cardiac events (MACE) [ Time Frame: Baseline to 12 months ]
    Incidence of adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization)

  36. Incidence of other significant clinical events [ Time Frame: Baseline to 6 months ]
    Incidence of other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade

  37. Incidence of other significant clinical events [ Time Frame: Baseline to 12 months ]
    Incidence of other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade

  38. Cumulative Days alive and out of hospital for heart failure [ Time Frame: Baseline to 12 months ]
    Days alive and out of hospital during the study evaluation period


Other Outcome Measures:
  1. Subjects with events between randomization and study product injection (SPI) that preclude the receipt of product [ Time Frame: Randomization to SPI ]
    Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product.

  2. Subjects who have a failed bone marrow aspiration procedure [ Time Frame: During bone marrow aspiration procedure ]
    Number and percent of subjects who do not successfully undergo bone marrow aspiration

  3. Subjects who have a failed endomyocardial biopsy procedure [ Time Frame: During endomyocardial biopsy procedure ]
    Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure

  4. Subject MSC products which failed release criteria [ Time Frame: Harvest to Study Product Injection Procedure ]
    Number and percent of subjects who have MSC products which failed release criteria

  5. Subject c-kit+ products which failed release criteria [ Time Frame: Harvest to SPI procedure ]
    Number and percent of subjects who have c-kit+ products which failed release criteria

  6. Subjects who receive less than 15 injections during SPI [ Time Frame: During SPI procedure ]
    Number and percent of subjects who received less than 15 injections during SPI

  7. Subjects who have at least one cardiac MRI endpoint measure that is uninterpretable [ Time Frame: Baseline to 12 months ]
    Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be ≥ 21 and <80 years of age
  2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF
  3. Have a "detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by cMRI
  4. Have an EF ≤ 40% by cMRI
  5. Be receiving guideline‐driven medical therapy for heart failure at stable and tolerated doses for ≥ 1 month prior to consent. For beta‐blockade "stable" is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose.
  6. Be a candidate for cardiac catheterization
  7. Have NYHA class I, II, or III heart failure symptoms
  8. If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection

Exclusion Criteria:

  1. Indication for standard-of-care surgery (including valve surgery, placement of left-ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for the treatment of ischemic and/or valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 4 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS status 1A or 1B, and they must have documented low probability of being transplanted
  2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe (any valve) insufficiency/regurgitation within 12 months of consent
  3. Aortic stenosis with valve area ≤ 1.5 cm2
  4. History of ischemic or hemorrhagic stroke within 90 days of consent
  5. History of a left ventricular remodeling surgical procedure utilizing prosthetic material
  6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted < 6 weeks prior to consent
    • non-transvenous epicardial, or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
    • any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated
  7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded)
  8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent
  9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)
  10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent
  11. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent
  12. Presence of LV thrombus
  13. Evidence of active myocarditis
  14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based predictive values
  15. Baseline eGFR <35 ml/min/1.73m2
  16. Blood glucose levels (HbA1c) >10%
  17. Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet count < 100,000/ul
  18. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the upper limit of normal (ULN)
  19. Coagulopathy (INR ≥ 1.3) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be excluded.
  20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV)
  21. Allergy to radiographic contrast material that cannot adequately be managed by premedication
  22. Known history of anaphylactic reaction to penicillin or streptomycin
  23. Received gene or cell-based therapy from any source within the previous 12 months
  24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated
  25. Condition that limits lifespan to < 1 year
  26. History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months
  27. Participation in an investigational therapeutic or device trial within 30 days of consent
  28. Cognitive or language barriers that prohibit obtaining informed consent or any study elements
  29. Pregnancy or lactation or plans to become pregnant in the next 12 months
  30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02501811


Locations
Layout table for location information
United States, California
Stanford University School of Medicine (Falk Cardiovascular Research Center)
Stanford, California, United States, 94305
United States, Florida
University of Florida-Department of Medicine
Gainesville, Florida, United States, 32610
University of Miami-Interdisciplinary Stem Cell Institute
Miami, Florida, United States, 33101
United States, Indiana
Indiana Center for Vascular Biology and Medicine
Indianapolis, Indiana, United States, 46202
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
United States, Texas
Texas Heart Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Study Chair: Robert Simari, MD CCTRN Steering Committee Chair

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Barry R Davis, Professor of Biostatistics, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT02501811    
Other Study ID Numbers: HSC-SPH-15-0413
5UM1HL087318 ( U.S. NIH Grant/Contract )
First Posted: July 17, 2015    Key Record Dates
Last Update Posted: January 29, 2020
Last Verified: January 2020
Keywords provided by Barry R Davis, The University of Texas Health Science Center, Houston:
Heart Failure
Ischemia
Autologous Stem Cells
LV dysfunction
Mesenchymal Stem Cells
c-kit+ Cells
Combination Cell Therapy
LV function
Functional status
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Cardiomyopathies
Ischemia
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Plasma-lyte 148
Ophthalmic Solutions
Pharmaceutical Solutions